Yunnan Baiyao Group Co., Ltd. operates within the Drugs, proprietaries, and sundries sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Yunnan Baiyao Group Co., Ltd. with three other
companies in this sector in China:
Zhejiang International Group Company Limited
sales of 17.26 billion Chinese Renmimbi [US$2.60 billion]
of which 100%
was Medicine Retailing),
China Medicine Health Industry Co Ltd
(25.74 billion Chinese Renmimbi [US$3.88 billion]
of which 67%
was Pharmaceutical Business), and
Huadong Medicine Company Limited
(25.38 billion Chinese Renmimbi [US$3.83 billion]
of which 79%
During the year ended December of 2016, sales at
Yunnan Baiyao Group Co., Ltd. were 22.41 billion Chinese Renmimbi (US$3.38 billion).
increase of 8.1%
versus 2015, when the company's sales were 20.74 billion Chinese Renmimbi.
This was the fifth consecutive year of sales increases at Yunnan Baiyao Group Co., Ltd.
(and since 2011, sales have increased a total of 98%).
Sales of Others saw an increase
that was more than double the company's growth rate: sales were up
78.9% in 2016, from
27.09 million Chinese Renmimbi to 48.48 million Chinese Renmimbi.
Yunnan Baiyao Group Co., Ltd. also saw significant increases in sales in
Comodities Trading (up 15.2% to 13.28 billion Chinese Renmimbi)
Not all segments of Yunnan Baiyao Group Co., Ltd. experienced an increase in sales in 2016:
sales of Technology Development fell 58.5% to 1.48 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).
Yunnan Baiyao Group Co., Ltd. also experienced decreases in sales in
Medicine Manufacturing (Industrial Tradi (down 1.1% to 9.08 billion Chinese Renmimbi)